Biotissue Holdings Inc.
$3.3M 20,909 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. reported $3,321,222.22 across General Payments, Research, and Ownership to 23,113 physicians and teaching hospitals across 23,378 transactions.
- $3.3M Top quartile payer
- All-tracks total
- 23,378 Top 10% volume
- Transactions
- 23,113 Top 10% reach
- Recipients
- −$231.2K
- General Payments vs PY2023
Paratek Pharmaceuticals, Inc. reported $3,321,222.22 across all CMS Open Payments tracks (General + Research + Ownership) to 23,113 physicians and teaching hospitals in Program Year 2024 - ranking #340 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,249,632.07, averaging $143.69 per recipient.
How Paratek Pharmaceuticals, Inc.'s $3.3M all-tracks total breaks down
Paratek Pharmaceuticals, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
B
85/100
Total payments
F
41/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
A
100/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer paratek-pharmaceuticals-inc Paratek Pharmaceuticals, Inc.
$3.3M · #340/1,925 · 0.0% industry · PY2024
- TOT $3.3M
- RANK #340
- SHARE 0.0%
- TXN 23,378
- RCP 23,113
- CAT 9
- GEN $1.2M
- ΔGEN −$231.2K
- TOP1 12.4%
- PY 2024
Volume peers
Nearest volume peer: Biotissue Holdings Inc. ($3.3M)
Paratek Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Paratek Pharmaceuticals, Inc.'s CMS-reported General Payments decreased by $231.2K (−15.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: PARATEK PHARMACEUTICALS, INC.PY2023: PARATEK PHARMACEUTICALS, INC.PY2024: Paratek Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,480,829.62
- PY2024
- $1,249,632.07
What the Data Shows for Paratek Pharmaceuticals, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Paratek Pharmaceuticals, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 9-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $514.1K, accounting for 41.1% of this company's General Payments and 22,441 transactions.
General Payment Breakdown by Type
Across 9 types of general payments, Paratek Pharmaceuticals, Inc.'s largest category was "Food and Beverage" at $514.1K - 41.1% of General Payments.
Paratek Pharmaceuticals, Inc. reports 9 general-payment categories - the top three are Food and Beverage (41.1%), Compensation for Services Other Than Consulting (32.7%), and Travel and Lodging (15.7%). The remaining 6 categories make up 10.4% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Paratek Pharmaceuticals, Inc. files across 9 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Paratek Pharmaceuticals, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $514.1K | 22,441 | 41.1% |
| Compensation for Services Other Than Consulting | $408.8K | 205 | 32.7% |
| Travel and Lodging | $196.6K | 345 | 15.7% |
| Consulting Fee | $112.4K | 43 | 9.0% |
| Space Rental or Facility Fees | $9.0K | 4 | 0.7% |
| Grant | $5.0K | 1 | 0.4% |
| Education | $3.1K | 71 | 0.2% |
| Gift | $435.36 | 1 | 0.0% |
| Entertainment | $179.39 | 2 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $407,436.58 (32.6%) of $1,249,632.07 in this company's General Payments records across 10,298 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Paratek Pharmaceuticals, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Andrew Dold
$155,391.51 across 223 reported transactions
- 2
Yoav Golan
$86,119.53 across 80 reported transactions
- 3
Warren Joseph
$76,196.43 across 66 reported transactions
- 4
David Wu
$59,150.00 across 12 reported transactions
- 5
Hector Brunet Rodriguez
$30,579.11 across 46 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Paratek Pharmaceuticals, Inc. ranks #340 of 1,925 by total payments (top 18% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,460 of 1,838 by HHI (bottom 21% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Sanara MedTech Inc. : $748.7K total payments, HHI 306
- Merz North America, Inc. : $3.5M total payments, HHI 306
- Silk Road Medical, Inc. : $2.8M total payments, HHI 303
- Balt USA, LLC : $457.3K total payments, HHI 303
- InspireMD Ltd : $11.0K total payments, HHI 302
- Synthes USA Products LLC : $235.8K total payments, HHI 302
- Paratek Pharmaceuticals, Inc. (this company) : $1.2M total payments, HHI 302
- Melinta Therapeutics, LLC : $573.7K total payments, HHI 300
- Avanos Medical : $867.2K total payments, HHI 298
- Atland Pharmaceuticals, LLC : $7.0K total payments, HHI 296
- Si-Bone, Inc. : $8.1M total payments, HHI 291
- Linde Gas & Equipment Inc. : $116.7K total payments, HHI 290
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Paratek Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Paratek Pharmaceuticals, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Paratek Pharmaceuticals, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Nielsen BioSciences, Inc.
$3.3M 0 recipients
Compare payment profiles
Merit Medical Systems Inc
$3.3M 1,352 recipients
Compare payment profiles
Oyster Point Pharma, Inc.
$3.3M 19,684 recipients
Compare payment profiles
LEO Pharma Inc.
$3.3M 38,155 recipients
Compare payment profiles
Elekta, Inc.
$3.4M 610 recipients
Compare payment profiles
Put this to use
Paratek Pharmaceuticals, Inc. ranks #340 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See where Paratek Pharmaceuticals, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Paratek Pharmaceuticals, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.